FDA continues to enforce CBD claims language as meeting on botanical is set for May
FDA has sent three companies marketing CBD products warning letters over disease claims. The warnings are the first issued under FDA’s de facto ‘enforcement discretion’ policy, which will be discussed at a meeting on CBD set for the end of May.